How is the Hans algorithm used to classify diffuse large B‑cell lymphoma (DLBCL) into germinal‑center B‑cell (GCB) and activated B‑cell (ABC/non‑GCB) subtypes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hans Algorithm for DLBCL Classification

The Hans algorithm classifies DLBCL into germinal center B-cell (GCB) and activated B-cell (ABC/non-GCB) subtypes using a sequential immunohistochemical evaluation of three markers: CD10, BCL6, and MUM1/IRF4.

How the Algorithm Works

The Hans algorithm follows a hierarchical decision tree:

  1. First, evaluate CD10:

    • If CD10 is positive → classify as GCB subtype
    • If CD10 is negative → proceed to next step
  2. Second, evaluate BCL6:

    • If BCL6 is positive → proceed to next step
    • If BCL6 is negative → classify as non-GCB/ABC subtype
  3. Third, evaluate MUM1/IRF4:

    • If MUM1 is positive → classify as non-GCB/ABC subtype
    • If MUM1 is negative → classify as GCB subtype

Clinical Significance

The GCB subtype demonstrates significantly better outcomes compared to the ABC/non-GCB subtype, with 5-year overall survival rates of approximately 68-70% versus 18-25%, respectively 1. The ABC subtype has worse prognosis when treated with R-CHOP and is characterized by constitutive activation of the NF-κB pathway 2.

Important Caveats and Limitations

Reproducibility Issues

While the Hans algorithm is widely used, published data on the prognostic effect of immunohistochemical techniques are contradictory, and it is not recommended to routinely base clinical decisions on these results 2. The ESMO guidelines explicitly state that cell of origin determined by IHC should not guide routine clinical decisions due to reproducibility concerns 2.

Specific Technical Challenges

  • CD10 staining shows high reproducibility across laboratories 3
  • MUM1 staining is inconsistent in 50% of cases, particularly when weak and heterogeneous 3, 4
  • BCL6 staining shows inconsistency in 40% of cases 3

High-Risk Discordant Patterns

Certain immunophenotypic patterns show significantly higher discrepancy rates (up to 46%) when compared to gene expression profiling 4:

  • CD10-/BCL6+/MUM1+ (classified as non-GCB by Hans)
  • CD10-/BCL6+/MUM1- with MUM1 expression around 30% threshold
  • Cases with aberrant triple positivity (CD10+/BCL6+/MUM1+) are genetically heterogeneous and enriched in IRF4 rearrangements 5

Agreement with Gene Expression Profiling

The Hans algorithm shows 69-86% concordance with gene expression profiling, which remains the gold standard 4, 1. The agreement rate improves to 86% after excluding unclassified cases 4.

Practical Recommendations

Gene expression profiling is the preferred method for cell-of-origin determination and is now used in clinical trials 2. However, when IHC must be used:

  • Ensure experienced hematopathologists perform the interpretation 3
  • Exercise particular caution with endoscopic biopsies from the gastrointestinal tract (higher discrepancy rate of 36%) 4
  • Be aware that cases with weak or heterogeneous MUM1 staining near the 30% cutoff require careful interpretation 4
  • Consider that the algorithm performs adequately in experienced hands with standardized protocols 6

The Hans algorithm remains a practical tool for routine practice when gene expression profiling is unavailable, but clinicians should recognize its limitations and avoid making critical treatment decisions based solely on IHC-derived cell-of-origin classification 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.